Showing posts with label WHO IGWG. Show all posts
Showing posts with label WHO IGWG. Show all posts

Wednesday, November 26, 2008

UN WHO Report Elevates Healthcare Access as Supreme Universal Human Right to Justify IP Rights Override & Promote Global Social Wealth Redistribution

http://whqlibdoc.who.int/publications/2008/9789241563703_eng.pdf

Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health


Final Report of the Commission on Social Determinants of Health


World Health Organization (© 2008)


In the spirit of social justice, the Commission on Social Determinants of Health was set up by the World Health Organization (WHO) in 2005 to marshal the evidence on what can be done to promote health equity, and to foster a global movement to achieve it.


As the Commission has done its work, several countries and agencies have become partners seeking to frame policies and programmes, across the whole of society, that influence the social determinants of health and improve health equity. These countries and partners are in the forefront of a global movement.
...We are indebted to the country partners of the Commission - the many government departments and officials who have supported our work with ideas, expert guidance, and invaluable critique, as well as financially. In particular we thank Fiona Adshead and Maggie Davies (England and United Kingdom); David Butler-Jones, Sylvie Stachenko, Jim Ball and Heather Fraser (Canada); Maria Soledad Barria, Pedro Garcia, Francisca Infante, Patricia Frenz (Chile); Paulo Buss, Alberto Pellegrini Filho (Brazil); Gholam Reza Heydari, Bijan Sadrizadeh, Alireza Olyaee Manesh (Islamic Republic of Iran); Stephen Muchiri (Kenya); Paulo Ivo Garrido, Gertrudes Machatine (Mozambique); Anna Hedin, Bernt Lundgren, Bosse Peterson (Sweden); Palitha Abeykoon, Sarah Samarage (Sri Lanka); Don Matheson, Stephen McKernan, Teresa Wall (New Zealand); and Ugrid Jindawatthana, Amphon Milintangkul (Thailand). (p. Acknowledgements)












[READERS SHOULD TAKE NOTE, IMMEDIATELY, OF THE COUNTRIES THAT UNDERWROTE THIS LESS THAN OBJECTIVE 'SPREAD THE WEALTH AROUND' UNITED NATIONS WHO REPORT. WHILE THREE ARE OECD MEMBERS - (UNITED KINGDOM/ENGLAND, SWEDEN [ALSO MEMBER STATES OF THE EUROPEAN UNION, A REGION WHICH HAS LONG CHAMPIONED A DIFFERENT LEGAL & ECONOMIC CONCEPT OF PRIVATE PROPERTY RIGHTS THAN THAT RECOGNIZED WITHIN THE UNITED STATES] & NEW ZEALAND), THE REMAINDER ARE EMERGING ECONOMIES (BRAZIL) OR DEVELOPING & LEAST DEVELOPED COUNTRIES (THAILAND, KENYA, SRI LANKA, MOZAMBIQUE, ISLAMIC REPUBLIC OF IRAN). THESE LATTER COUNTRIES LACK ADEQUATE NATIONAL HEALTHCARE, EDUCATION, AND ECONOMIC SYSTEMS FOR A VARIETY OF REASONS, INCLUDING, BUT NOT LIMITED TO, MASSIVE GOVERNMENT CORRUPTION AND LACK OF RESPECT FOR THE 'RULE OF LAW' ESPECIALLY INTELLECTUAL PROPERTY RIGHTS. THE RELATIVELY HIGHER COST OF ESSENTIAL (TEMPORARILY) PATENT-PROTECTED MEDICINES AND MEDICAL DEVICES IS THE LEAST OF THEIR PROBLEMS. IN FACT, BRAZIL AND THAILAND HAVE BEEN AMONG THE MOST ACTIVE STATE ANTAGONISTS ON THE WORLD STAGE TO PROMOTE A NEW GLOBAL PARADIGM THAT SEEKS TO WEAKEN IP RIGHTS, & PRIVATE PROPERTY RIGHTS IN GENERAL, IN THE NAME OF 'HUMAN RIGHTS', AS CAN BE DISCERNED FROM PRIOR ENTRIES CITING DETAILED RESEARCH REFERENCED ELSEWHERE WITHIN THIS BLOG.]

The Commission calls on the WHO and all governments to lead global action on the social determinants of health with the aim of achieving health equity. It is essential that governments, civil society, WHO, and other global organizations now come together in taking action to improve the lives of the world’s citizens. Achieving health equity within a generation is achievable, it is the right thing to do, and now is the right time to do it.


…The Commission takes a holistic view of social determinants of health. The poor health of the poor, the social gradient in health within countries, and the marked health inequities between countries are caused by the unequal distribution of power, income, goods, and services, globally and nationally, the consequent unfairness in the immediate, visible circumstances of peoples lives – their access to health care, schools, and education, their conditions of work and leisure, their homes, communities, towns, or cities – and their chances of leading a flourishing life. This unequal distribution of health-damaging experiences is not in any sense a ‘natural’ phenomenon but is the result of a toxic combination of poor social policies and programmes, unfair economic arrangements, and bad politics. Together, the structural determinants and conditions of daily life constitute the social determinants of health and are responsible for a major part of health inequities between and within countries.


The global community can put this right but it will take urgent and sustained action, globally, nationally, and locally. Deep inequities in the distribution of power and economic arrangements, globally, are of key relevance to health equity. This in no way implies ignoring other levels of action. There is a great deal that national and local governments can do; and the Commission has been impressed by the force of civil society and local movements that both provide immediate local help and push governments to change.


[THIS IS A REFERENCE TO THE ACTIVIST COMMUNITIES AROUND THE WORLD THAT PROMOTE 'SOCIAL PARITY' OVER 'ECONOMIC, TECHNOLOGICAL & SOCIAL PROGRESS'.]


And of course climate change has profound implications for the global system – how it affects the way of life and health of individuals and the planet. We need to bring the two agendas of health equity and climate change together. Our core concerns with health equity must be part of the global community balancing the needs of social and economic development of the whole global population, health equity, and the urgency of dealing with climate change.


A new approach to development

['NEGATIVE' ENVIRONMENT & HEALTH-CENTRIC SUSTAINABLE DEVELOPMENT]


The Commission’s work embodies a new approach to development. Health and health equity may not be the aim of all social policies but they will be a fundamental result.


Take the central policy importance given to economic growth: Economic growth is without question important, particularly for poor countries, as it gives the opportunity to provide resources to invest in improvement of the lives of their population. But growth by itself, without appropriate social policies to ensure reasonable fairness in the way its benefits are distributed, brings little benefit to health equity.


(p.1 EXECUTIVE SUMMARY)


… The Commission’s overarching recommendations:


…2. Tackle the Inequitable Distribution of Power, Money, and Resources


In order to address health inequities, and inequitable conditions of daily living, it is necessary to address inequities – such as those between men and women – in the way society is organized. This requires a strong public sector that is committed, capable, and adequately financed. To achieve that requires more than strengthened government – it requires strengthened governance: legitimacy, space, and support for civil society, for an accountable private sector, and for people across society to agree public interests and reinvest in the value of collective action. In a globalized world, the need for governance dedicated to equity applies equally from the community level to global institutions.


… Three principles of action:


2. Tackle the inequitable distribution of power, money, and resources – the structural drivers of those conditions of daily life – globally, nationally, and locally.

(p. 2)


…1. Improve Daily Living Conditions


The inequities in how society is organized mean that the freedom to lead a flourishing life and to enjoy good health is unequally distributed between and within societies.

(p. 3)


…SOCIAL PROTECTION ACROSS THE LIFECOURSE


All people need social protection across the lifecourse, as young children, in working life, and in old age. People also need protection in case of specific shocks, such as illness, disability, and loss of income or work.


Evidence for action


Low living standards are a powerful determinant of health inequity. They influence lifelong trajectories, among others through their effects on ECD. Child poverty and transmission of poverty from generation to generation are major obstacles to improving population health and reducing health inequity. Four out of five people worldwide lack the back-up of basic social security coverage (ILO, 2003).


Redistributive welfare systems, in combination with the extent to which people can make a healthy living on the labour market, influence poverty levels. Generous universal social protection systems are associated with better population health, including lower excess mortality among the old and lower mortality levels among socially disadvantaged groups.


Budgets for social protection tend to be larger, and perhaps more sustainable, in countries with universal protection systems; poverty and income inequality tend to be smaller in these countries compared to countries with systems that target the poor.


Extending social protection to all people, within countries and globally, will be a major step towards securing health equity within a generation…


What must be done


Reducing the health gap in a generation requires that governments build systems that allow a healthy standard of living below which nobody should fall due to circumstances beyond his or her control. Social protection schemes can be instrumental in realizing developmental goals, rather than being dependent on achieving these goals – they can be efficient ways to reduce poverty, and local economies can benefit.


Establish and strengthen universal comprehensive social protection policies that support a level of income sufficient for healthy living for all.


• Progressively increase the generosity of social protection systems towards a level that is sufficient for healthy living.

(p.7)


……UNIVERSAL HEALTH CARE


Access to and utilization of health care is vital to good and equitable health. The health-care system is itself a social determinant of health, influenced by and influencing the effect of other social determinants. Gender, education, occupation, income, ethnicity, and place of residence are all closely linked to people’s access to, experiences of, and benefits from health care. Leaders in health care have an important stewardship role across all branches of society to ensure that policies and actions in other sectors improve health equity.


Evidence for action


Without health care, many of the opportunities for fundamental health improvement are lost. With partial health-care systems, or systems with inequitable provision, opportunities for universal health as a matter of social justice are lost.


…The Commission considers health care a common good, not a market commodity. Virtually all high-income countries organize their health-care systems around the principle of universal coverage (combining health financing and provision).



Universal coverage requires that everyone within a country can access the same range of (good quality) services according to needs and preferences, regardless of income level, social status, or residency, and that people are empowered to use these services. It extends the same scope of benefits to the whole population. There is no sound argument that other countries, including the poorest, should not aspire to universal health-care coverage, given adequate support over the long term. The Commission advocates financing the health-care system through general taxation and/or mandatory universal insurance.

(p.8)


HEALTH EQUITY IN ALL POLICIES, SYSTEMS, AND PROGRAMMES


Every aspect of government and the economy has the potential to affect health and health equity – finance, education, housing, employment, transport, and health, just to name six. Coherent action across government, at all levels, is essential for improvement of health equity.


Evidence for action


Different government policies, depending on their nature, can either improve or worsen health and health equity (Kickbusch, 2007).


…Reaching beyond government to involve civil society and the voluntary and private sectors is a vital step towards action for health equity. The increased incorporation of community engagement and social participation in policy processes helps to ensure fair decision-making on health equity issues.


…Making health and health equity a shared value across sectors is a politically challenging strategy but one that is needed globally.



What must be done


Place responsibility for action on health and health equity at the highest level of government, and ensure its coherent consideration across all policies.


• Make health and health equity corporate issues for the whole of government, supported by the head of state, by establishing health equity as a marker of government performance.


• Assess the impact of all policies and programmes on health and health equity, building towards coherence in all government action.

(pp. 10-11)


… Fair Financing


Public finance to fund action across the social determinants of health is fundamental to welfare and to health equity.


Evidence for action


For countries at all levels of economic development, increasing public finance to fund action across the social determinants of health – from child development and education, through living and working conditions, to health care – is fundamental to welfare and health equity. Evidence shows that the socioeconomic development of rich countries was strongly supported by publicly financed infrastructure and progressively universal public services.



The emphasis on public finance, given the marked failure of markets to supply vital goods and services equitably, implies strong public sector leadership and adequate public expenditure. This in turn implies progressive taxation – evidence shows that modest levels of redistribution have considerably greater impact on poverty reduction than economic growth alone. And, in the case of poorer countries, it implies much greater international financial assistance.

(p. 12)


… What must be done:


Strengthen public finance for action on the social determinants of health.


• Build national capacity for progressive taxation and assess potential for new national and global public finance mechanisms.


Increase international finance for health equity, and coordinate increased finance through social determinants of health action framework.


• Honour existing commitments by increasing global aid to the 0.7% of GDP commitment, and expand the Multilateral Debt Relief Initiative; enhance action on health equity by developing a coherent social determinants of health focus in existing frameworks such as the Poverty Reduction Strategy Paper.


Fairly allocate government resources for action on the social determinants of health.


• Establish mechanisms to finance cross-government action on social determinants of health, and to allocate finance fairly between geographical regions and social groups.

(p.13)


Market Responsibility


Markets bring health benefits in the form of new technologies, goods and services, and improved standard of living. But the marketplace can also generate negative conditions for health in the form of economic inequalities, resource depletion, environmental pollution, unhealthy working conditions, and the circulation of dangerous and unhealthy goods.


Evidence for action


Health is not a tradable commodity. It is a matter of rights and a public sector duty. As such, resources for health must be equitable and universal.



There are three linked issues. First, experience shows that commercialization of vital social goods such as education and health care produces health inequity. Provision of such vital social goods must be governed by the public sector, rather than being left to markets.



Second, there needs to be public sector leadership in effective national and international regulation of products, activities, and conditions that damage health or lead to health inequities. These together mean that, third, competent, regular health equity impact assessment of all policy-making and market regulation should be institutionalized nationally and internationally.


The Commission views certain goods and services as basic human and societal needs – access to clean water, for example, and health care. Such goods and services must be made available universally regardless of ability to pay. In such instances, therefore, it is the public sector rather than the marketplace that underwrites adequate supply and access.

(p.14)


… Public sector leadership does not displace the responsibilities and capacities of other actors: civil society and the private sector. Private sector actors are influential, and have the power to do much for global health equity. To date, though, initiatives such as those under corporate social responsibility have shown limited evidence of real impact. Corporate social responsibility may be a valuable way forward, but evidence is needed to demonstrate this. Corporate accountability may well be a stronger basis on which to build a responsible and collaborative relationship between the private sector and public interest.

(p.15)


[A responsible private sector - Private sector actors can behave in ways that undermine public interest, but they can also contribute powerfully to public good. There is some evidence of small moves towards greater social contribution, but it is of limited credibility. Corporate social responsibility has been promoted as a vehicle for improving the positive social impacts of private sector actors. To date, however, corporate social responsibility is often little more than cosmetic. One of its principal shortcomings is that, being voluntary, it lacks enforcement (Box 12.20), but also that little evaluation has been attempted. An exception to this problem is the Ethical Trading Initiative. An independent evaluation of the impact of the Ethical Trading Initiative Code of Labour Practice, for example, reported a number of areas of improvement (Barrientos & Smith, 2007). But voluntary initiatives will inevitably be limited in their impact. Corporate accountability may be a more meaningful approach. (p. 142) – FINAL REPORT]


…Good Global Governance


Dramatic differences in the health and life chances of peoples around the world reflect imbalance in the power and prosperity of nations. The undoubted benefits of globalization remain profoundly unequally distributed.


…Through the recognition, under globalization, of common interests and interdependent futures, it is imperative that the international community re-commits to a multilateral system in which all countries, rich and poor, engage with an equitable voice. It is only through such a system of global governance, placing fairness in health at the heart of the development agenda and genuine equality of influence at the heart of its decision-making, that coherent attention to global health equity is possible.


What must be done


Make health equity a global development goal, and adopt a social determinants of health framework to strengthen multilateral action on development.


• The United Nations, through WHO and the Economic and Social Council, to adopt health equity as a core global development goal and use a social determinants of health indicators framework to monitor progress.


• The United Nations to establish multilateral working groups on thematic social determinants of health


– initially early child development, gender equity, employment and working conditions, health-care systems, and participatory governance.


Strengthen WHO leadership in global action on the social determinants of health, institutionalizing social determinants of health as a guiding principle across WHO departments and country programmes.

(p. 19)


…ACTORS


Above, we set out the key actions called for in the recommendations. Here, we describe those on whom effective action depends. The role of governments through public sector action is fundamental to health equity. But the role is not government’s alone.


…Multilateral agencies


An overarching Commission recommendation is the need for intersectoral coherence – in policy-making and action – to enhance effective action on the social determinants of health and achieve improvements in health equity. Multilateral specialist and financing agencies can do much to strengthen their collective impact on the social determinants of health and health equity…


…WHO


WHO is the mandated leader in global health. It is time to enhance WHO’s leadership role through the agenda for action on the social determinants of health and global health equity.


…National and local government


Underpinning action on the social determinants of health and health equity is an empowered public sector, based on principles of justice, participation, and intersectoral collaboration. This will require strengthening of the core functions of government and public institutions, nationally and sub-nationally, particularly in relation to policy coherence, participatory governance, planning, regulation development and enforcement, and standard-setting. It also depends on strong leadership and stewardship from the ministry of health, supported by WHO.


…Civil society


As community members, grassroots advocates, service and programme providers, and performance monitors, civil society actors from the global to the local level constitute a vital bridge between policies and plans and the reality of change and improvement in the lives of all. Helping to organize and promote diverse voices across different communities, civil society can be a powerful champion of health equity.


…Private sector


The private sector has a profound impact on health and wellbeing. Where the Commission reasserts the vital role of public sector leadership in acting for health equity, this does not imply a relegation of the importance of private sector activities. It does, though, imply the need for recognition of potentially adverse impacts, and the need for responsibility in regulation with regard to those impacts. Alongside controlling undesirable effects on health and health equity, the vitality of the private sector has much to offer that could enhance health and wellbeing.


Actions include:


• Strengthening accountability: Recognize and respond accountably to international agreements, standards, and codes of employment practice; ensure employment and working conditions are fair for men and women; reduce and eradicate child labour, and ensure compliance with occupational health and safety standards; support educational and vocational training opportunities as part of employment conditions, with special emphasis on opportunities for women; and ensure private sector activities and services (such as production and patenting of life-saving medicines, provision of health insurance schemes) contribute to and do not undermine health equity.


• Investing in research: Commit to research and development in treatment for neglected diseases and diseases of poverty, and share knowledge in areas (such as pharmaceuticals patents) with life-saving potential.


…• Generating and disseminating social determinants of health knowledge: Ensure research funding is allocated to social determinants of health work; support the global health observatory and multilateral, national, and local crosssectoral working through development and testing of social determinants of health indicators and intervention impact evaluation; establish and expand virtual networks and clearing houses organized on the principles of open access, managed to enhance accessibility from sites in all high-, middle-, and low-income settings; contribute to reversal of the brain drain from low- and middle-income countries; and address and remove gender biases in research teams, proposals, designs, practices, and reports.

(pp. 22-23)


…FINAL REPORT


…ACTIONS FOR MARKET RESPONSIBILITY


The Commission recommends that:


12.1 WHO, in collaboration with other relevant multilateral agencies, supporting Member States, institutionalize health equity impact assessment, globally and nationally, of major global, regional, and bilateral economic agreements (see Rec 10.3; 16.7).


A key recommendation from the Commission is that caution be applied by participating countries in the consideration of new global, regional, and bilateral economic (trade and investment) policy commitments. Before such commitments are made, understanding the impact on health and health equity is vital. WHO should re-affirm its global health leadership by initiating a review of trade and investment agreements – working collaboratively with other multilateral agencies – with a view to institutionalizing health equity impact assessment as a standard part of all future agreements.


WHO can also strengthen the capacity of Member States, their ministries of health, and civil society organizations to prepare positions for bilateral and multilateral trade negotiations. To do this, WHO will need to augment its existing research and policy expertise, including economics, law, and the social sciences. Specific attention needs to be given to addressing trade-related negotiations on domestic regulation, subsidies, and government procurement – and those affecting globally organized production and financial markets – and trade in goods and services with direct effects on health.


BOX 12.4: WORLD HEALTH ORGANIZATION: DIAGNOSTIC TOOL AND
COMPANION WORKBOOK IN TRADE AND HEALTH – A PRIORITY FOR 2008/2009



WHO is working with WTO, the World Bank, World Intellectual Property Organization, UNCTAD, international experts, and trade and health policymakers from 10 countries to develop a diagnostic tool and companion workbook on trade and health. This new phase of work adopts a more systematic and broader perspective on the linkages between trade and health. The diagnostic tool examines five components of that relationship: 1) macroeconomics, trade, and health; 2) trade in health-related products, including medicines and intellectual property related issues; 3) trade in products hazardous to health, such as tobacco products; 4) trade in health services – e-commerce, health tourism, foreign direct investment in health, cross-border movement of health professionals; and 5) trade in foodstuffs.


The diagnostic tool and its companion workbook, which document best practices, data sources, decision trees, and international norms and standards, will be ready for implementation in 2009. The implementation of the diagnostic tool will enable policy-makers to develop national policies and strategies related to trade and health and to identify their capacity-building needs in this area.

(p. 135)


…Health equity impact assessment in economic agreements


Since the health equity implications of international agreements and their impact on national policies and programmes are not always fully evident, health equity impact assessment is key to coherent cross-government policies and programmes. It is essential that health equity assessment be applied to policies or major programmes outside the health sector, too (MEKN, 2007a) (see Chapter 16: The Social Determinants of Health: Monitoring, Research, and Training).


The institutionalization of health equity impact assessment is clearly still in its infancy – and presents real issues in terms of required technical skills and institutional capacity in many countries, especially those with low and middle incomes. However, the example of environmental impact assessment provides some basis for optimism. Notwithstanding serious recognized shortfalls in the methodology, conduct, and enforcement of environmental impact assessment, environmental impact has become – in the space of a generation – a widely acknowledged criterion in the processes of policy-making across the board.


Flexibility in agreements


Commitment to trade agreements should not constrain signatory countries, after signing, from acting to mitigate unforeseen adverse impacts on health and health equity. There is a clear need for more flexibility in the way signatory status to international agreements can be modified over time. The General Agreement on Trade in Services (GATS) provides exceptions in cases of environmental or health hazard, but the provision is narrow and appears to require demonstration of actual harm, limiting national capacity to exercise precautionary measures (Box 12.7).

(p. 136)


Although flexibilities are formally written into the Trade-related Aspects of Intellectual Property Rights (TRIPS) agreements, governments – particularly in many low- and middle-income countries with limited technical and institutional capacity – have in many cases derived only limited benefit from such flexibilities, and have in others been encouraged not to use them at all (Box 12.8).


At a more general level, international market-related trade agreements could include more strongly worded provisions by which countries with widely different needs and developmental strategies can opt out of their signatory status (for limited periods and under transparent conditions) where domestic conditions – including evidence of adverse impact on health and health equity – suggest the need (Box 12.9).

(p. 137)


…Health care


A core objective of all health-systems policy must be to ensure that everyone has access to competent, quality care independently of ability to pay (see Chapter 9: Universal Health Care). Theoretically, market regulation can shape the role and behaviour of the private sector within the health system. In practice, evidence that it can do so in ways that enhance health equity is lacking. Until governments have demonstrated their ability to effectively regulate private investment and provision in health services in ways that enhance health equity, they should avoid making any health services commitments in binding trade treaties that affect their capacities to exercise domestic regulatory control. It is not clear that any government, anywhere in the world, has met this test (HSKN, 2007; GKN, 2007). The example of health insurance is instructive. It is clear that health insurance can support health-care financing, but it must not, in so doing, undermine health equity (Box 12.12).

(p. 139)


…POWER, MONEY AND RESOURCES PART 4


ACTION TOWARDS FAIRNESS IN VOICE AND INCLUSION


Political empowerment for health and health equity requires strengthening the fairness by which all groups in a society are included or represented in decision-making about how society operates, particularly in relation to its effect on health and health equity. Such fairness in voice and inclusion depends on social structures, supported by the government, that mandate and ensure the rights of groups to be heard and to represent themselves – through, for example, legislation and institutional capacity – and on specific programmes supported by those structures, through which active participation can be realized.


Beyond these, fairness depends on the growth of civil society organizations, networks, and movements and their progressive ability to challenge inequity and push for the installation of equity – in general and in relation to health – in the centre of all existing and emerging political debates.


Legislation for political empowerment – rights and agency The right to the conditions necessary to achieve the highest attainable standard of health – Article 12 of the International Covenant on Economic, Social and Cultural Rights – is principally concerned with disadvantaged groups, participation, and accountability and lies at the heart of the health and human rights movement (Hunt, 2007). General Comment 14 (2000) is a substantive instrument which confirms that the right to the conditions for health not only encompasses access to health care, but also includes the underlying determinants of health, such as safe water, adequate sanitation, a healthy environment, health-related information, and freedom from discrimination (UN, 2000a). Fundamental to the progressive realization of this right is the ratification, operationalization, and monitoring of General Comment 14 and associated actions. WHO, in collaboration with other international agencies and the UN Special Rapporteur on the Right to the Highest Attainable Standard of Health (see Chapter 15:


Good Global Governance), supports states in the adoption and implementation of General Comment 14.


…Underpinning the realization of rights, fair participation, and inclusion in decision-making and action that affects health and health equity are transparent, accountable, and participative political and legal systems that build on and reinforce authentic participation.

(pp. 158-159)


…Bottom-up approaches to health equity - While the empowerment of social groups through their representation in policy-related agenda-setting and decisionmaking is critical, so too is empowerment for action through bottom-up, grassroots approaches (Sibal, 2006). The struggles against the injustices encountered by the most disadvantaged in society, and the process of organizing these people, builds local people’s leadership. It is empowering. It gives people a greater sense of control over their lives and future. This empowerment permeates all aspects of their lives.


…The enactment of legal changes to recognize and support community empowerment initiatives will ensure the comprehensive inclusion of disadvantaged groups in action at global, national, and local levels concerned with improving health and health equity.

(p. 162)


…BOX 14.8: BARRIO ADENTRO – THE RIGHT TO HEALTH AND SOCIAL INCLUSION IN BOLIVARIAN REPUBLIC OF VENEZUELA


The Venezuelan Constitution firmly establishes the right to health and the citizen’s duty to take an active part in the management of health. The draft bill of the new General Health Law declares that participation and social control in health is a constitutional right of all citizens and that they have the right to make decisions, intervene, and exercise direct control, with autonomy and independence, in all matters related to the formulation, planning, and regulation of health sector policies, plans, and projects, as well as the evaluation, control, and monitoring of health-sector management and financing.

(p. 163)


…While it is critical that community members share control over processes that affect their lives, without political commitment and leadership and allocation of resources such initiatives can be short lived…


There are notable examples where an explicit rights agenda has been successfully applied to global governance. In the case of TRIPS and AIDS medicines, civil society-driven action from South Africa, with worldwide take-up, created a ‘norm cascade’ leading to immediate and structural changes not only in the market accessibility of life-saving drugs, but in the global understanding of questions of intellectual property and the application of appropriate norms for global health equity (Box 14.12).

(p. 164)


…Social movements


For changes in power, there also needs to be space for challenge and contest by social movements. Although social movements and community organizations tend to mobilize around concrete issues in local everyday life, their actions are clearly rooted in and address structures and processes that extend far beyond this local realm. These movements tend to take one of three forms: political societies (e.g. political parties, pressure groups, lobbying groups), which seek influence within the political arena; civil societies such as trade unions, peasant organizations, and religious movements; and civil-political societies that combine or link the activities of political and civil societies (e.g. labour movements, women’s movement, antiapartheid movement).


The People’s Health Movement (http://phmovement. org/) is a large global civil society network of health activists supportive of the WHO policy of Health for All and organized to combat the economic and political causes of deepening inequities in health worldwide and to call for the return to the principles of Alma Ata. Support for People’s Health Movement and other similar civil society organizations such as the global antipoverty movement and labour movement will help to ensure that action on the social determinants of health is developed, implemented, and evaluated.


A society concerned with better and more equitably distributed health is one that challenges unequal power relations through participation, ensuring all voices are heard and respected in decision-making that affects health equity. Being more inclusive requires social policies, laws, institutions, and programmes to protect human rights. It requires inclusion of individuals and groups to represent strongly and effectively their needs and interests in the development of policy. And it requires active civil society and social movements. It is clear that community or civil society action on health inequities cannot be separated from the responsibility of the state to guarantee a comprehensive set of rights and ensure the fair distribution of essential material and social goods among population groups (Solar & Irwin, 2007). Top-down and bottom-up approaches are equally vital.


BOX 14.12: TAKING ACTION ON RIGHTS AND TRADE: THE CASE OF AIDS MEDICINES


“The human right to health requires the provision of essential medicines as a core duty that cannot be traded for private property interests or domestic economic growth. This right may provide a means of achieving a more public health-oriented formulation, implementation and interpretation of trade rules by domestic courts, governments and the WTO alike. The growing power of this right is similarly reflected in an emerging jurisprudence where medicines have been successfully claimed under human rights protections”.


A decade ago, the high cost of AIDS medicines led WHO and UNAIDS to advise that treatment was not a wise use of resources in poorer countries. Prevention of HIV/AIDS was preferred over treatment. There was no international funding for developing countries to purchase drugs and companies gave extremely limited price concessions. A dramatic battle for AIDS medicines ensued that peaked in 2001 in the Pharmaceutical Manufacturer’s Association case in South Africa. Between 1997 and 2001, the United States and 40 pharmaceutical companies used trade pressures and litigation to prevent the South African government from passing legislation to access affordable medicines.


Industry claimed that the legislation (and the parallel importing it authorized) breached TRIPS and South Africa’s Constitution and threatened industry’s incentive to innovate new medicines. The pharmaceutical companies went to court in South Africa. An extraordinary level of public action accompanied the case, attracting global censure against the corporations. In April 2001, the pharmaceutical companies withdrew their case.


A norm cascade followed, with a sharp upsurge at the UN in international statements on treatment as a human right and articulations of state obligations on antiretroviral therapy. The same year saw the WTO issue its Declaration on TRIPS and Public Health.


These rhetorical commitments were matched by considerable policy and price shifts. Antiretroviral therapy prices in many low-income countries dropped from US$ 15 000 to US$ 148-549 per annum. New global funding mechanisms were created, such as the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, the United States PEPFAR and the World Bank Multi-Country HIV/AIDS Program for Africa. In 2002, WHO adopted the activist goal of placing 3 million people on antiretroviral therapy and, in late 2005, shifted upwards to the goal of achieving universal access to treatment by 2010, a goal similarly adopted by the UN General Assembly and by the G8. In 5 years, access to antiretroviral therapy in sub-Saharan Africa has increased from under 1% to current levels of 28%. Source: Forman, 2007

(p. 165)

Tuesday, May 6, 2008

Anti-IP Movement Dealt Devasting Blow at WHO; Yet Touts 'Progress Made' in Effort at Positive 'Spin' Control


[READERS WILL NOTICE HOW THE TONE OF INTERNAL COMMUNICATIONS BETWEEN THE MEMBERS/ REPRESENTATIVES OF KNOWLEDGE ECOLOGY INTERNATIONAL (KEI), AN ANTI-INTELLECTUAL PROPERTY NON-GOVERNMENTAL ORGANIZATION, ABOUT THE RESULTS OF RECENT MEETINGS CONVENED AT THE WORLD HEALTH ORGANIZATION BY THE INTERGOVERNMENTAL WORKING GROUP ON INTELLECTUAL PROPERTY AND HEALTH, CHANGED FROM ‘NEGATIVE’ TO ‘POSITIVE’, SUCH THAT, THE LATER PUBLICIZED ARTICLES RELEASED THROUGH INTELLECTUAL PROPERTY WATCH, GRADUALLY CREATE A ‘POSITIVE SPIN’.]


The following exchange was reflected on the listserv of ip-health@lists.essential.org .


[FRANCISCO ROSSI SETS FORTH TO HIS COLLEAGUES THAT THE WHO IGWG MEETING WAS AN UTTER FAILURE B/C THEY COULD NOT, AT SUCH MEETING, SECURE COMMITTMENTS ON ANTI-PATENT INITIATIVES. YET, HE TRIED TO PLACE A 'POSITIVE SPIN' ON THE OUTCOME...]


On Mon, 2008-05-05 at 15:07 +0000, Francisco Rossi wrote:


[Picked text/plain from multipart/alternative]


From: Francisco Rossi
To: ip-health
Subject: RE: [Ip-health] FT: WHO fails to strike drug deal
Date: Mon, 5 May 2008 15:07:38 +0000


Dear All:


I just want to introduce some reflexions on IGWG outcomes, because I believe there are some elements to take into account. Despite I could have reasons to be especially disapointed, from a personnal perspective, I think we need to be more objective and balanced. Certainly any assessment of IGWG outcomes is related on expectations.


If we expected a radical re-formulation of IP worldwide, IGWG was a major failure. If our expectations were oriented to introduce alternative incentive models instead of prevelent ones, meeting was a failure.


In the other hand, if we read the meeting as an step on a process to put developing countries points of view in the table. IGWG was a major sucess. If we read the meeting as a strong movement on the WHO secretariat to take very seriously IP issues, meeting was a major success.


I was commenting with some friends that in the past we were working very reactive against TRIPS, and then against FTAs and Trips plus measures. Reactive and in a defensive Perspective. Now, despite the UN lenguage in most of the agreements and consensus, there is a open door for the negotiation on Innovation, IP and Public health.


Certainly developed countries and interested industries were there to obstacle any movement. And they worked pretty well. By from my personal point of view they lost a lot. And I would like to highlight the developing world countries leadership on that.


Just to re-open this discussion.


Best to all


Francisco Rossi

------------------------------------------------------------------------------------------------

[IN COMFORTING, FRANCISCO ROSSI, JAMIE LOVE OF KEI POINTS OUT THE 'POSITIVES'...]


From: James Love
Reply-To: james.love@keionline.org
To: Francisco Rossi
Cc: ip-health
Organization: http://www.keionline.org
Date: Mon, 05 May 2008 16:56:02 -0400

This is a response to the comment by Francisco Rossi.


The IGWG negotiations involve a wide range of topics, and people will see useful text in several areas, although also important areas where there is no progress yet, as reflected in the 18 paragraphs still with brackets. There is also relatively weak language in some parts.


In terms of new incentives, good language on incentives has in fact moved ahead. For example:

-----------
5.3(a) explore and, where appropriate, promote a range of incentive schemes for research and development including addressing, where appropriate, the de-linkage of the costs of research and development and the price of health products, for example, through the award of prizes,
with the object of addressing diseases which disappropriately affect developing countries (consensus)


---------


It was difficult to get 5.3(a). But there is now very good language, on what we consider a key issue.


7.1, while not as strong as the language in the deleted 7.3, is also useful.


". . .examine current financing and coordination of research and development, as well as proposals for new and innovative sources of financing to stimulate R&D related to Type II and Type III diseases and the specific R&D needs of developing countries in relationship to Type I
diseases."


In the closing plenary, Barbados said it was assured that its proposals for prizes would be covered by the language in 7.1 (new and innovative sources of financing to stimulate R&D). The Barbados intervention led to a procedural question by the USA, followed immediately by substantive support for the Barbados position by India.


There is also plenty of useful language in other sections of the document on this topic, including the front parts (some of which were changed from the draft now on the web).


My own view is that very good progress has been done on the topic of new incentive nechanisms that are not linked to prices of products. This was aided in part by the generally favorable response to substance and concrete nature of the Barbados/Bolivia prize proposals.


What the IGWG did not do was fund anything, not only for prizes, but for grants and other push funding, or AMCS (which are no longer mentioned in the text) or anything else. The US and Europe did not want to talk about money at this meeting. For a number of groups that are looking for something important for funding neglected diseases, this was a major flaw in the negotiations so far. The idea of a biomedical treaty is alive, and the expert working group on financing R&D will carry the conversation forward, but this is clearly a delay that is driven by a lack of political commitment to spend new money in this area.


The debates in May at the WHA will focus on the 18 important paragraphs where there is no consensus. People can usefully begin focusing on these paragraphs, and push their delegations to do the right thing.

Jamie

-------------------------------------------------------------------------------------------------

http://www.ip-watch.org/weblog/index.php?p=1024


Intellectual Property Watch


2 May 2008


WHO Members Inch Toward Consensus On IP, Innovation And Public Health


By Kaitlin Mara and William New


Members of the World Health Organization (WHO) gathered this week to address innovation and intellectual property issues in public health saw hope for agreement on a strategy paper focused on the needs of developing countries, particularly on neglected diseases. But with two days remaining in the negotiations, difficult issues on intellectual property rights and the action plan remained unresolved.


The WHO Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) is meeting from 28 April to 3 May, as a part of its resumed second session (the second session begin in November 2007)(IPW, WHO, 9 November 2007). The current round of negotiations is under mandate to create a consensus document for presentation at the World Health Assembly, which will take place later this month.


Draft Global Strategy on Public Health, Innovation and Intellectual Property as of start of 2 May, 2008 [pdf]


In her opening remarks to the IGWG, WHO Director-General Margaret Chan said that an “agreed framework can make the cycle of product discovery, development and delivery more efficient and more sensitive to health needs in the developing world” by giving the international community a “common tool” to leverage against health problems. She stressed the importance of the negotiations moving forward “as rapidly and efficiently as possible,” and urged a continuation of the “sense of urgency” seen in past months.


Further pressure for resolution has been placed on negotiators by some developed countries who would like to see the IGWG discussions end this week, and to pull the WHO back from involvement with IP issues, according to some participants. Others thought that the negotiations should not be rushed, and one developing country official said, “I hope we don’t do in haste what we will repent later.”


This week’s debate is the result of several years of intensive discussion at the WHO on policies to address the problem that the existing intellectual property system lacks economic incentives for the private sector to invest in research and development (R&D) for diseases primarily affecting those who cannot afford to pay the higher prices necessary to recover R&D costs.


But a larger issue of the role of the WHO in discussions relating to intellectual property is underlying the talks. Many feel the issues belong primarily in the World Trade Organization, World Intellectual Property Organization, or in national laws. But others see the WHO with the lead on public health issues as having been sidelined in global debates as they relate to IP and public health, even as those debates have resulted in rules that have possibly had a pejorative effect on public health.


“The IGWG is a historic opportunity and this should not become a historic failure for lack of response,” Médicins sans Frontières’ Tido von Schoen-Angerer told the plenary. “Governments, and the WHO, must not abdicate from their responsibilities, or pass the buck to others. We are asking you to strengthen WHO’s role in intellectual property and health, to change the way R&D is prioritised and financed so that paying for the research does not equal prohibitive prices, and to take measures to increase generic competition.”


Draft Text Taking Shape


While most negotiations have happened behind closed doors, on 1 May WHO members met as a whole in an attempt to hammer out consensus on the draft global strategy on public health. The talks were able to cover elements two, three and four out of the eight-element draft strategy - covering, respectively, promoting research and development, building and improving innovative capacity, and transfer of technology - and had begun to discuss element five, on the application and management of intellectual property to contribute to innovation and promote public health.


Remaining aspects of element five are expected to be contentious, according to some participants. In general, consensus is being achieved through a relative weakening of provisions, often, but not always, along north-south lines. Compromises involved the insertion of phrases like “possible” and “appropriate.”


The morning’s negotiations focussed on element two, promotion of research and development. Convergence was reached on accessibility to libraries and technical support to create compound libraries in developing countries (Article 2.2.b), and the related article (2.4.c) on the creation of open databases and compound libraries. The United States sought to delete the second article as it felt it was redundant, sparking discussion on the issue.


The dissemination of publicly or donor-funded medical inventions and know-how (Article 2.4.d), and the “incorporation of research exemptions in legislation of developing countries” for public health purposes (Article 2.4.e) were both contested by the United States. Korea agreed with the US on 2.4.d, as one of the suggested ways to disseminate medical know-how was through open licensing and the Korean delegate was unsure if his country had a policy allowing for such licensing.


Brazil and India felt that open licensing was a useful addition to the paragraph, and India mentioned that the use of open source technologies in India was very effective. Jamaica supported India and Brazil. A distinction also was made between proprietary and non-proprietary databases. A compromise was reached with the language “including but not limited to open licensing.”


On 2.4.e, which reads “consider the incorporation of research exemptions in legislation of developing countries to address public health needs, consistent with the TRIPS and the Doha declaration on TRIPS and Public Health,” the United States asked for the paragraph to be deleted, as such issues would be dealt with in the IP chapter (element 5). Delegations pointedly asked the US delegation to explain its problem with research exemptions, as they are covered in both the TRIPS agreement and in US legislation. Japan supported the United States, which argued that the term ‘research exemptions’ was not well-defined, and it was unclear as to its actual scope.


The encouragement and promotion of traditional knowledge (and traditional medicines) was another key debate. Suriname wanted to ensure that traditional medicine is protected from being carried away from its nations of origin and brought back as patented matter. The traditional knowledge clause in element 5, Article 5.1.f, on the creation of digital libraries of traditional knowledge in order to prevent misappropriation, caused much disagreement. Some delegates were uncertain if discussions on traditional knowledge even belonged in the WHO negotiation. Others could not see how a digital database could prevent misappropriation, as it would offer greater access to the knowledge. Several new suggestions were offered, but after lengthy discussion no convergence was forthcoming so the chair suggested interested parties meet outside the plenary. Kenya is chairing this side session.


Another discussion in element 5 reflected a debate that has arisen at other institutions in Geneva that the training on IP in developing countries, such as of patent examiners, should fully reflect public health priorities.


Element 5 seems likely to be difficult to negotiate, with upcoming discussions on provisions such as how to address research involving humans. Delegates on 1 May discussed Article 5.1 and several of its subsections, but had trouble reaching consensus on several topics. In addition to traditional knowledge, a clause on strengthening “education and training in the granting, application and management of intellectual property from a public health perspective” also presented a problem. The US wanted to strike the word “granting” from the paragraph, and other members proposed adding specific references to flexibilities contained in the TRIPS agreement and other instruments. Consensus was unable to be reached.


Under Article 5.1, on the management of intellectual property in a manner that maximises health-related innovation, Suriname was concerned about the ethics of clinical trials, citing examples in which such trials have been conducted in developing countries, aiding medical innovation on drugs that were subsequently out of the price range of individuals who had participated in trials. Suriname wishes to add “maximises health related innovation and access” to the clause; consensus is pending agreement on that addition.


Civil Society Views


The hottest points of disagreement have tended to arise over practical solutions for solving this problem, reflected in the wide variation in proposals from civil society groups addressing negotiators. Public interest advocacy group Knowledge Ecology International’s Jamie Love has suggested prizes and prize funds replace [correction: his position is that they would coexist, see comment below] patents for neglected diseases, and expressed disappointment that most references to such systems in the strategy paper appeared to be surrounded by brackets indicating lack of consensus on their presence in the text. Love suggested that if the governments are not ready at this point in time to achieve real improvements, then perhaps the process should wait for another time.


International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Director General Harvey Bale said the industry group wants to preserve strong intellectual property protection, which it says promotes innovation, and instead focus on market incentives outside of IP, such as advanced market commitments (AMC) and “fast track” approval for drugs targeting developing country diseases. An AMC is a guarantee of a market in the event a medication or vaccine is developed in order to incentivise the development of health solutions in diseases or for areas where the existence of a market is uncertain or too small to compensate for R&D costs.


Health Action international also said that WHO must have a clear mandate to work in IP and health, and that the final draft strategy should not dilute flexibilities in IP enforcement already guaranteed under the WTO’s Trade-Related Aspects of Intellectual Property Rights Agreement. The European Generic Medicines Association and the International Generic Pharmaceutical Alliance, represented by Greg Perry, said data exclusivity must not be used to create market exclusivity beyond patent protection.


“IGWG must systematically address innovation and access to medicines” and should “delink the cost of research and development from the price of developed products,” said Sarah Rimmington of Churches’ Action for Health. The role of WHO should be strengthened on IP and issues in health, and the organisation should “provide active guidance, specifically on TRIPS flexibilities.”


The International Alliance of Patients Organizations called for IGWG recognise patients and patient organisations as key stakeholders.


MSF’s von Schoen-Angerer urged that the medical R&D process be government-led, and said it appeared wealthy countries objected to a proposed R&D fund without offering alternatives.


Kaitlin Mara may be reached at kmara@ip-watch.ch. William New may be reached at wnew@ip-watch.ch.


-------------------------------------------------------------------------------------------------

http://www.ip-watch.org/weblog/index.php?p=1027


Intellectual Property Watch


6 May 2008


WHO IP And Health Group Concludes With Progress; Tough Issues Remain For Assembly


By Kaitlin Mara and William New


The World Health Organization (WHO) negotiations on public health, intellectual property and innovation ended Saturday with substantial progress toward consensus on a draft strategy but with a plan of action remaining and the most contentious articles in the strategy still under brackets - indicating lack of agreement - as the paper goes to the World Health Assembly.


The air in the room was cautiously optimistic as WHO Director General Margaret Chan’s closing comments praised the assembled delegates at the 28 April to 3 May Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) for reaching consensus on 107 paragraphs (many through deletions) that had been unresolved at the meeting’s start Monday.


The group’s mandate from the 2006 Health Assembly was to agree on a strategy and plan of action to boost research and development of, and access to, treatments for diseases disproportionately affecting developing countries, in time for this year’s annual assembly. If sufficient agreement is reached on the remaining items and the plan of action, implementation of the strategy should follow.


But there was also a sense from many delegates that substantive work lies ahead, and some nongovernmental organisations expressed disappointment at the IGWG’s perceived lack of strong commitment to public health, and the potential lost opportunity to make a profound difference.


While the global strategy being drafted by the group is not legally binding, it is being taken seriously by governments and other stakeholders because it could have a significant impact on policy. “It is a political document,” said one official. “It can have a lot of weight.”


Both developing and developed countries representatives found positive things to highlight about the IGWG, though it is clear that outcomes are not yet guaranteed and large gaps remain between what different stakeholders want from the draft strategy. Much of the work was done in closed informal sessions, often into the night, participants said.


Some key outcomes or debates were the proposed creation of an expert group on financing and the coordination of R&D, a mention of prizes as a possible alternative incentive for research and development, and policies on human clinical trials, competition, counterfeit medicines, and the role of the WHO on international IP and innovation issues.


Also significant was the apparent removal of advance market commitments, which would have created a mechanism for ensuring a market for new drugs, sources said. One source also said there was now a separation of provisions relating to access from those relating to intellectual property rights.


Ambassador Tom Mboya Okeyo of Kenya said the outcome’s impact will take time to see but that it was a good step. He noted consensus on provisions on access to medicines, and on flexibilities in the international IP system to accommodate access. Also agreed were several provisions that could strengthen innovation on essential medicines and encourage sustainable financing mechanisms, and provisions that could help protect traditional medical knowledge, all of which are important to developing countries, he said. The next challenges are in ensuring the key actions outlined in the strategy are implemented quickly, he said, adding that he hoped the WHO director general could mobilise funds for that purpose.


Suriname delegate Miriam Naarendorp called the week’s outcome the “start of the battle,” with the plan of action and implementation issues still to come. However, it was an important start, as, Naarendorp said, the IGWG was able to identify issues important to developing countries, and that the developing nations “stood firm on things that mattered” and had created a document that the WHO could not ignore.


An official from a leading developing country praised the outcome as successful as “so many member states agreed on so many things.” And a third developing nation delegate added that “we’ve made tremendous progress here [and] I expect we will get it finished at the World Health Assembly.” The assembly meets from 19 to 24 May.


A key developed country source was more concerned that the IGWG seemed to have averted potential negative consequences, saying that “the possibility of impact on the IP system has been reduced” and that “there were a lot of proposals that could have undermined innovation.”


Nongovernmental groups had higher hopes going into the meeting, for an outcome with profound effects on health product development for the poor. Over one hundred civil society organisations and patients groups signed a “joint declaration” (pdf) stating that “health is a fundamental human right and a necessary condition for human dignity” and calling for the IGWG to find sustainable solutions to encourage both innovation in healthcare and access to the fruits of that innovation, and several eminent academics signed a similar statement asking for IGWG delegates to consider “the exploration of new and innovative mechanisms that seek to correct the deficiencies of the current system” of drug development and delivery.


Draft Strategy Text Advances


The latest available version of the draft strategy was from the start of the last day, 3 May. Click here to read the 3 May version [pdf].


Delegates were able to reach full consensus on five out of eight elements within the draft global strategy, which includes principles for using the intellectual property system to maximise public health impact, particularly in innovation related to developing country diseases. Full consensus sections were element 1, on prioritising research and development needs; element 2, on promoting research and development; and element 3, on building and improving innovative capacity.


Article 3.4 outlines ways to support “policies that will promote innovation based on traditional medicine,” as well as Article 3.5.b, which encourages “the establishment of award schemes for health-related innovation.”


Article 5.3.a, which also saw consensus, mentions prizes as an innovation incentive, an issue important to developing countries and some nongovernmental participants. Barbados and Bolivia submitted a document at the outset of the week’s meeting proposing alternative incentive schemes for drug innovation in the form of prize funds for inexpensive tuberculosis diagnostic testing, for a Chagas disease treatment, for priority medicines and vaccines, and for cancer treatments. The document also calls for a global agreement on funding clinical trials as public goods.


Element 4, on transfer of technology, was largely agreed upon, with the exception only of element 4.1.b, which reads “promote transfer of technology and production of health products in developing countries through investment and capacity building, including by providing guidance on appropriate technologies.” As of the end of 2 May, this article was listed “consensus pending USA.” One developing country official said that in general the United States was “a bit tough” in negotiation, referring to the fact that the country was often the sole voice blocking consensus (though there may have been others unspoken). The US delegation included an IP negotiator from the US Trade Representative’s office.


Element 7, on promoting sustainable financing mechanisms, also reached full consensus, as did element 8, on the establishment of monitoring and reporting systems. The agreement on element 7 was reached only after a lengthy debate, Barbados said during the IGWG’s closing plenary session. Article 7.3, which detailed several strategies for the establishment of a global R&D fund to address gaps in diseases affecting developing countries, including the use of prizes and rewards as well as earmarked funds for patent buyouts to ensure access to medicines, was deleted by consensus.


Barbados asked during the final plenary that it be officially noted that this consensus was predicated on an understanding by Barbados and the rest of the Caribbean group, as well as Bolivia, that these issues be addressed under 7.1.a. That article calls for the establishment of a “results-oriented and time-limited expert working group under the auspices of the WHO and linking up with other relevant groups to examine current financing and coordination of research and development, as well as proposals for new and innovative sources of financing to stimulate research and development” relevant to developing countries.


Element 5, on the application and management of intellectual property to contribute to innovation and promote public health, and element 6, on improving delivery and access, proved the hardest on which to reach consensus.


Still remaining to be resolved are issues of data-sharing, specifically through the creation of easy-to-use global databases on the status health-related patents (under article 5.1.c); on the training of patent examiners in intellectual property application and management, and possibly on TRIPS flexibilities (under article 5.1.e); on promoting competition to increase availability of health products under article 6.3, and particularly on support for the production/introduction of generic medicines (under 6.3.a). Another issue under debate in the strategy related to agreements that impose stricter intellectual property standards than agreements in the multilateral system (so-called TRIPS-plus provisions).


On 5.1.h, which originally stated, “establish measures to avoid unethical experiments involving human beings as a requirement for registration of medicines and technologies,” sparked a lengthy discussion on 2 May on the nature of ethics in human testing. Points discussed included: the difference between clinical tests for new drugs, or the bioequivalence tests done when generics are marketed, the ethics of testing new drugs against placebos when existing treatments are available for comparative testing (the Declaration of Helsinki, which lays out ethics of healthcare research, and says that new methods of treatment should be tested against the best existing treatments, where available, and not placebos), and the ethics of repeating a clinical test because the original tester has exclusive control over the results of first test and will not make the data public. Also of interest, especially to developing countries, was ensuring post-trial access to drugs by study participants, which the Declaration of Helsinki calls “necessary.”


The article eventually passed consensus on the condition it be moved from element 5.1 on information sharing and capacity building on health-related innovation to element 6.2, which covers ethical review and quality/safety regulation. The final text reads: “promote ethical principles for clinical trials involving human beings as a requirement of registration of medicines and health-related technologies, with reference to the Declaration of Helsinki, and other appropriate texts, on ethical principles for medical research involving human subjects, including good clinical practice guidelines.”


Other debates under element 5 included a provision on preventing anti-competitive practices related to IP rights, language on encouraging respect for flexibilities in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and a possible clause on counterfeit health products, including a definition. Some sources said an effort is being made to clarify the distinction between counterfeit products and generic products.


Also under element 5, a discussion was held on the role of the WHO on IP-related matters. Officials present from the World Intellectual Property Organization and the World Trade Organization signalled resistance to a proposal to create a formal coordinating body between agencies under Article 5.1.i. Creating a formal coordination effort would, a WIPO official said, just “add governance issues” to the already functioning informal collaboration that currently exists.


One participant said an informal relationship was seen as possibly minimising interagency turf battles. Still, some participants viewed the outcome as having strengthened the role of the WHO in IP issues. Consensus Article 5.1.f states, “strengthen efforts to effectively coordinate work relating to intellectual property and public health among the secretariats and governing bodies of relevant regional and international organizations (including WHO, WIPO and WTO) to facilitate dialogue and dissemination of information to countries.”


The traditional knowledge debate discussed earlier in the week (IPW, Public Health, 1 May 2008) was resolved after the Kenyan-led informal session came up with the text “facilitate, where feasible and appropriate, possible access to traditional medicinal knowledge for use a s prior art in examination of patents, including, where appropriate, the inclusion of traditional knowledge information in digital libraries.”


Lost Opportunities and Some Progress


Concerned entities and other nongovernmental organisations participating at the event were not entirely pleased with the outcome of the negotiating process.


Médecins Sans Frontières (MSF) sharply criticised the IGWG, saying it had “failed to take concrete action towards reforming a medical innovation system that largely disregards the health needs of millions of people in developing countries.” Tido von Schoen-Angerer, director of MSF’s access to medicines campaign said that negotiators had not “risen to the challenge” of “prescrib[ing] change to a broken system.” He called the working group a “lost opportunity,” particularly because there had been no consensus on the development of alternative research and development incentives.


Ethan Guillen, executive director of Universities Allied for Essential Medicines (UAEM) also expressed surprise at “the lack of bold commitment by most of the rich countries” and said “that there had to be stiff negotiations on the idea that the cost of medicines impedes access in the developing world makes you wonder if some negotiators hadn’t noticed that busloads of American retirees have to hop across the US border to Canada to get drugs they can afford.”


Sarah Rimmington, an attorney at public interest organisation Essential Action, said IGWG was meant to address how “the current corporate sector system of medical R&D, which is based on patent monopolies, has largely failed people in developing countries.” Rimmington said while the IGWG had taken an “important first step by agreeing to explore some common sense measures to address this failure,” such as innovation incentives not reliant on patent monopolies, consensus on actual implementation processes was not reached. This lack of agreement was, she added, largely due to “resistance from developed countries such as the United States, the EU, and Canada” and added that it “is hard not to wonder if pressure from the brand-name pharmaceutical industry - which is based in developed countries and remains ideologically committed to patent monopolies - influenced this disappointing outcome.”


[AS NOTED IN THE PRIOR ARTICLE DATED MAY 2ND, SARAH RIMMINGTON IS ALSO THE REPRESENTATIVE OF ANOTHER NON-GOVERNMENTAL ORGANIZATION THAT PARTICIPATED IN THE IGWG MEETINGS: Churches’ Action for Health.]


Jamie Love of Knowledge Ecology International said the IGWG “did next to nothing on identifying R&D priorities, estimating funding needs, or creating a framework for sustainable funding for priority R&D, three tasks central to its mission.”


Harvey Bale, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), when asked about whether this meeting represented progress toward the goal of addressing the problem of neglected diseases, said it “has lost focus on that,” but added that there was hope it could come back. He stressed the importance of advanced market commitments, or guarantees of a market in the event a medication or vaccine is developed (which were deleted from the draft strategy). He also stressed the importance of partnerships for development that link companies and the public sector in coordinated research efforts.


But there were also some positive views. Guillen said his group was “pleased to see the advancement… of important issues like technology transfer” in the draft strategy and said UAEM is “hopeful that consensus recommendations on open licensing and other technology transfer provisions agreed to during this round will send a strong message to universities… to adopt policies that will free up the tools of innovation and make medicines discovered on campuses available at low-cost in the developing world.”


Love was pleased to see that advanced market commitments had come out of the draft strategy and prizes had been included.


Nicoletta Dentico, policy and advocacy manager at the Drugs for Neglected Diseases Initiative (DNDi) said “the outcome of this intense week-long negotiation shows that some uncertain lights are looming, but still in a forest of thick shadows” that research on essential medicines still faces the “resistance of those who have set the direction of innovation so far” but that hopefully the “"spirit of Geneva” [would] clear, in the face of poor people’s needs, the shadows.”


MSF has said that, as the IGWG failed to arrive at strong conclusions, it is now up to the World Health Assembly “to translate bold ideas into concrete action.”


Kaitlin Mara may be reached at kmara@ip-watch.ch. William New may be reached at wnew@ip-watch.ch.